Linus Pauling once remarked that in order to have good ideas, you have to have lots of them. The same is true of drug candidates for lymphoma. This regularly updated page offers a guide through the files of potential new therapies that were deemed unworthy.
Mitumprotimit-T (Specifid) -- This was one of several vaccine candidates which initially seemed as though it might show promise for follicular lymphoma. In 2008, Favrille admitted that a Phase 3 trial of mostly untreated patients, comparing rituximab monotherapy with rituximab plus Specifid, had failed to show any benefit versus a placebo.
No comments:
Post a Comment